Indivior Share Discussion Threads

[thedoghouser] 30/11/2018 17:43

Doesn’t this happen pre takeover?

[tsmith2] 30/11/2018 15:13

Prepay debt - interesting

[tsmith2] 30/11/2018 09:45

Looking good...chart turned

[tsmith2] 29/11/2018 09:27

I'd put it down to poor comprehension

[w1ndjammer] 29/11/2018 09:14

pwhite

so is BP. didn`t help them in 2010

Dr reddy is headquartered in India and trade in Rupee`s

WJ.

[tsmith2] 29/11/2018 08:12

Clearly you don't understand English Aggregate of Standard Life Aberdeen plc affiliated investment management entities with delegated voting rights on behalf of multiple managed portfolios City and country of registered office Edinburgh, Scotland

[pwhite73] 29/11/2018 07:58

Dr Reddy's is listed on the New York Stock Exchange.

It is not Standard Life that is increasing its holdings its small traders like yourself through various nominee accounts and small managed funds.

These holding news announcements are all immaterial. You have to wait for the two big news items I have highlighted above.

[tsmith2] 28/11/2018 14:57

holding statement out - would explain yesterday's weakness. someone snapping them though..

[w1ndjammer] 27/11/2018 14:03

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India.





WJ.

[w1ndjammer] 27/11/2018 13:56

numpty alert HOoo dear pwhite strikes again


Global Headquarters

Indivior Inc.

North Chesterfield, Virginia, USA

T [phone]

F [phone]




WJ.

[pwhite73] 27/11/2018 12:20

Maybe but I know a bit about shares and how the US courts are shamelessly bias towards US companies. No foreign owned company will threaten the hegemony of US companies in their own backyard. There are two major drops to come. 1. When Dr Reddys start selling their generic drug. 2. When INDV advise on its financial constraints. Don't be holding when either is announced.

[tsmith2] 27/11/2018 11:31

You have no idea about business..

[pwhite73] 27/11/2018 11:24

The market cap is about £700m. That is an outrageous valuation for the destruction in value as a result of the US court decision.

[tsmith2] 26/11/2018 08:37

good early volume and price action..in

[tsmith2] 25/11/2018 09:53

and the company has already made a provision of that much...

[tsmith2] 25/11/2018 09:53

that's bullocks...Litigation UpdateThe Group carries a provision for investigative and antitrust litigation matters of $438m. Substantially all of the provision relates to the U.S. Department of Justice investigation. The Group is in advanced discussions with the Department of Justice about a possible resolution to its investigations, although it cannot predict with any certainty whether, when, or at what cost it will reach an ultimate resolution.It's a provision for many matters only one of them being Dr Reddy..#desperate

[pwhite73] 25/11/2018 09:22

Yes it is tempting but within the next few weeks Dr Reddy's will confirm if it is to start selling its generic drug. If this announcement is made the stock will plunge again. Furthermore as per the Q3 results the company will incur legal costs of $438m and is anticipating this would be material higher if they were to lose the case against Dr Reddy's which they have. You see by taking legal action against Dr Reddy's they have prevented Dr Reddy's from selling their generic drug and now have to compensating them for loss of sales, profit, reputation and legal costs.

[tsmith2] 23/11/2018 15:54

shown good strength today, strength into finish would be bullish.tempted

[dealy] 23/11/2018 09:39

the company has a proven track record of bringing drugs to market. it has net cash and will generate significant cash flow this year. it is worth substantially more than 750m gbp

[adrian j boris] 23/11/2018 08:18

Oliver Haill
WebFG News
23 Nov, 2018 07:38 23 Nov, 2018 07:38
Indivior gets small dose of pain relief from Canada


As it battles a legal headache in the US, Indivior had some good news north of the border on Friday, as where regulators approved its new long-lasting treatment for opioid addiction.


Health Canada gave the green light to Sublocade, an extended-release buprenorphine injection, for the management of moderate to severe opioid use disorder in adults.

Canada saw 3,996 and 3,005 apparent opioid-related deaths in 2017 and 2016, with at least 1,036 in the first quarter of 2018, according to a special advisory committee on the 'epidemic of opioid overdoses'.


Indivior has made much slower progress with Sublocade than hoped. Since being approved in the US last December and launched at the beginning of March, the company has only sold $5m of the drug in the US, including $3m in the third quarter of 2018.

[pwhite73] 23/11/2018 08:00

RNS out but it is worthless. Investors should expect a string of vacuous RNS announcements over the next few months to try and mitigate against the US court decision and boost a flagging share price.

[buywell3] 23/11/2018 01:21

What a bunch of tw@ts that took this to 500p in 2018

And that was after the chances of USA legal actions were known

Amazing the amount of investors funds that have been squandered

Do some still buying thinking that a small company based outside the USA in the UK is going to win a ruling in their favor in American courts ?

Averaging down is not a wise thing when the facts are very much V the reality of the situation

USA BIG PHARMA is running the show



Buyers of this share are taking on the USA BIG PHARMA lobby in the states ... and the FDA and other regulatory USA bodies

Who is going to win ?

[kirk 6] 22/11/2018 16:51

Good day considering markets down this will be a winner tomorrow

[pwhite73] 22/11/2018 14:08

The brokers would now be given the task of flogging the stock ahead of the next fund raise.